Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.62 |
| ▸ | GRPR | P30550 | 2/20 | 0.62 |
| ▸ | CCKBR | P32239 | 2/20 | 0.59 |
| ▸ | GLP1R | P43220 | 2/20 | 0.59 |
| ▸ | PRLHR | P49683 | 5/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.57 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599104 | 0.87 | NPY1R (0.65) | GLP1RPRLHRKISS1RNPY1RNPY2R | |
| SCHEMBL31441008 | 0.84 | CXCR4 (0.63) | CCKBRGLP1RPRLHRNPY1RNPY2R | |
| SCHEMBL29455091 | 0.83 | KISS1R (0.59) | NMBRGRPRKISS1RNPY1RNPY2R | |
| SCHEMBL31105379 | 0.83 | NPY1R (0.64) | CCKBRGLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL38664590 | 0.83 | NPY1R (0.57) | CCKBRGLP1RPRLHRKISS1RNPY1R | |
| Dynorphin A (1-17) SCHEMBL29599476 | 0.82 | OPRD1 (0.70) | NMBRGRPROPRD1 | |
| Dynorphin A (1-17) SCHEMBL29358748 | 0.82 | OPRD1 (0.70) | NMBRGRPROPRD1 | |
| SCHEMBL31182444 | 0.82 | NPY2R (0.70) | CCKBRGLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL29811065 | 0.82 | NPY2R (0.71) | CCKBRGLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL38654334 | 0.82 | NPY2R (0.70) | GLP1RPRLHRNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2026-03-31 | — | — | US | disclosed |
| US-12583900-B2 | Peptide conjugates and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4626459-A1 | PALMITOYLATED ANALOGUE OF PROLACTIN-RELEASING PEPTIDE FOR INTRANASAL ADMINISTRATION | Ustav organicke chemie a biochemie Akademie ved CR, v.v.i. (CZ) | 2025-10-08 | — | — | EP | disclosed |
| EP-3621632-B1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-08-22 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024114846-A1 | PALMITOYLATED ANALOGUE OF PROLACTIN-RELEASING PEPTIDE FOR INTRANASAL ADMINISTRATION | USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V. V. I. (CZ) | 2024-06-06 | — | — | WO | disclosed |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2023-07-20 | — | — | US | disclosed |
| US-20230071371-A1 | PEPTIDE CONJUGATES AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2023-03-09 | — | — | US | disclosed |
| CN-115232201-A | PrRP31 modified by polyethylene glycol and preparation and application thereof | 西北工业大学 | 2022-10-25 | — | — | CN | disclosed |
| EP-4069274-A1 | PEPTIDE CONJUGATES AND METHODS OF USE | The Scripps Research Institute (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115052615-A | Peptide conjugates and methods of use | 斯克利普斯研究所 | 2022-09-13 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NMBR 1416/4885GRPR 936/4885CCKBR 2086/4885 |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | VIP, HAMP, HM13 | NMBR 3567/4885GRPR 669/4885CCKBR 3032/4885 |
| US-12583900-B2 | Peptide conjugates and methods of use | GIPR, GLP1R, GCG | NMBR 1671/4885GRPR 4/4885CCKBR 16/4885 |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | VIP, NGLY1, SPPL2B | NMBR 2546/4885GRPR 588/4885CCKBR 2734/4885 |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | NMBR 2546/4885GRPR 588/4885CCKBR 2734/4885 |
| US-20230071371-A1 | PEPTIDE CONJUGATES AND METHODS OF USE | GIPR, GLP1R, GRPR | NMBR 756/4885GRPR 3/4885CCKBR 25/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NMBR 1416/4885GRPR 936/4885CCKBR 2086/4885 |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | NMBR 2546/4885GRPR 588/4885CCKBR 2734/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | NMBR 1403/4885GRPR 775/4885CCKBR 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.